Lesinurad

BreastfeedingPediatric
  • TRADE NAMES: Duzallo (AstraZeneca); Zurampic (AstraZeneca)
  • INDICATIONS: Gout-associated hyperuricemia (in combination with a xanthine oxidase inhibitor)
  • CLASS: URAT1 inhibitor, Uricosuric
  • HALF-LIFE: 5 hours

FDA APPROVAL DATE: 12/22/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Carbamazepine, CYP2C9 inducers or inhibitors, CYP3A substrates, Fluconazole, Rifampin, Valproic Acid

PREGNANCY CATEGORY: N/A
No available data

Contra-indicated in patients with severe renal impairment (including end stage renal disease, kidney transplant recipients or patients on dialysis), tumor lysis syndrome or Lesch-Nylan syndrome.

Duzallo is lesinurad and allopurinol (see separate entry).

RISK OF ACUTE RENAL FAILURE, MORE COMMON WHEN USED WITHOUT A XANTHINE OXIDASE INHIBITOR

See full prescribing information for complete boxed warning.

Our database has 24 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.


Page last updated 08/31/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top